Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Clinical-trials-phase-iii symbols : ALNY save search
Alnylam to Present Additional Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the Heart Failure Society of America Annual Scientific Meeting 2022
Published: 2022-09-13 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.78%
H: 0.0%
C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.97%
H: 0.16%
C: -0.98%
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: -1.77%
H: 0.54%
C: -0.8%
america meeting heart study
Alnylam to Present Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the 18th International Symposium on Amyloidosis
Published: 2022-08-18 (Crawled : 12:20) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -5.88%
H: 3.23%
C: 3.23%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -1.55%
H: 0.0%
C: 0.0%
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: 0.38%
H: 0.39%
C: -0.23%
symposium international study
Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
Published: 2022-08-03 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.6%
H: 0.0%
C: -0.76%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.17%
H: 0.12%
C: -1.29%
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: 47.44%
H: 0.0%
C: 0.0%
topline positive results study
Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
Published: 2022-05-24 (Crawled : 12:00) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 1.04%
H: 1.53%
C: 1.37%
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: -3.53%
H: 0.0%
C: -1.2%
results phase 3
Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran
Published: 2022-05-23 (Crawled : 12:00) - biospace.com/
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: 2.06%
H: 0.0%
C: 0.0%
cardiac results phase 3
Alnylam Presents Positive Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
Published: 2021-11-05 (Crawled : 22:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -1.65%
H: 0.0%
C: 0.0%
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
positive results positive results phase 3
Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
Published: 2021-10-27 (Crawled : 21:00) - biospace.com/
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: -0.42%
H: 0.24%
C: -3.2%
positive results topline phase 3
Alnylam Presents Additional 9-Month Data from HELIOS-A Phase 3 Study of Vutrisiran at the European ATTR (EU-ATTR) Amyloidosis Meeting
Published: 2021-09-07 (Crawled : 12:00) - biospace.com/
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: -4.76%
europe phase 3
Alnylam Completes Enrollment in HELIOS-B Phase 3 Study of Investigational Vutrisiran in Patients with Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy
Published: 2021-08-09 (Crawled : 12:15) - biospace.com/
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: 0.37%
H: 4.18%
C: 3.46%
media phase 3 cardio enroll
Alnylam Announces New Data from ATTR Amyloidosis Programs at the Peripheral Nerve Society’s 2021 Annual Meeting
Published: 2021-06-07 (Crawled : 12:00) - biospace.com/
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: 0.19%
H: 3.41%
C: 3.14%
Alnylam Completes Enrollment in APOLLO-B Phase 3 Study of Patisiran in Transthyretin-Mediated (ATTR) Amyloidosis Patients with Cardiomyopathy
Published: 2021-06-01 (Crawled : 12:00) - biospace.com/
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: 0.17%
H: 2.05%
C: 1.44%
media phase 3 cardio enroll
Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO® (lumasiran)
Published: 2021-05-03 (Crawled : 12:00) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -4.18%
H: 1.62%
C: 1.41%
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: -0.11%
H: 0.09%
C: -3.66%
positive results phase 3
Alnylam Presents Positive Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran
Published: 2021-04-19 (Crawled : 19:00) - biospace.com/
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: -0.39%
H: 1.79%
C: -0.68%
positive results positive results phase 3
Alnylam Completes Enrollment in ILLUMINATE-C Phase 3 Study of Lumasiran, an RNAi Therapeutic, for the Treatment of Advanced Primary Hyperoxaluria Type 1
Published: 2020-12-03 (Crawled : 16:00) - biospace.com/
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: 0.41%
H: 2.21%
C: 0.9%
phase 3 treatment enroll
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.